# US 2025/0325005 A1 · Feed additive compositions and methods for using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0325005 A1
- Document ID: US20250325005A1
- Status: Published application
- Kind: A1
- Application number: 18/683,985
- Filed: 2022-08-22
- Published: 2025-10-23
- Earliest claimed: 2021-08-23
- Assignees: International N&H Denmark Aps
- Applicants: International N&H Denmark Aps
- Inventors: Charlotte Horsmans POULSEN; Jonathan PETERSON; Tanja Maria GRUBER
- Web page: https://patentgrep.com/patent/US20250325005A1

## CPC

- A23K 20/189: Enzymes
- A23K 20/195: Antibiotics
- A23K 50/30: for swines
- A23K 50/60: for weanlings
- C12Y 302/01051: Alpha-L-fucosidase (3.2.1.51)
- Y02P 60/22: Methane [CH4], e.g. from rice paddies
- A23K: FODDER
- C12Y: ENZYMES
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

Provided herein, inter alia, are methods for improving animal health (such as gut health) and performance as well as decreasing methane emissions via administration of an effective amount of a glycoside hydrolase capable of removing at least one alpha-1,2-L-fucose moiety from an intestinal mucin layer. Such methods improve animal health and performance without the need to administer potentially harmful antibiotics to the livestock.

## Claims

### Claim 1

A method for improving gut health in an animal comprising administering to the animal an effective amount of a glycoside hydrolase capable of removing at least one alpha-1,2-L-fucose moiety from an intestinal mucin layer.

### Claim 2 (depends on 1)

The method of claim 1, wherein improving gut health comprises one or more of a) promoting growth of one or more commensal intestinal bacterial; b) decreasing growth of one or more methanogenic archaea; c) increasing the quantity of intestinal IgA; d) decreasing the quantity of intestinal neutrophil levels; e) increasing average daily feed intake (ADFI) of the animal; f) decreasing mortality; and/or g) improving feed conversion ratio (FCR).

### Claim 3 (depends on 1)

The method of claim 1, wherein the commensal bacteria comprise Prevotella spp. and/or Megasphaera spp.

### Claim 4 (depends on 1)

The method of claim 1, wherein the methanogenic archaea comprises Methanobrevibacter spp.

### Claim 5 (depends on 4)

The method of claim 4, wherein the methanogenic archaea comprises M. smithii.

### Claim 6 (depends on 1)

The method of claim 1, wherein the glycoside hydrolase is an alpha-L-1,2 fucosidase.

### Claim 7 (depends on 6)

The method of claim 6, wherein the alpha-L-fucosidase is selected from the group consisting of glycoside hydrolase family 95 (GH95) and glycoside hydrolase family 29 (GH 29).

### Claim 8 (depends on 1)

The method of claim 1, wherein the method further comprises administering to the animal an effective amount of at least one direct fed microbial.

### Claim 9 (depends on 1)

The method of claim 1, wherein the method further comprises administering to the animal an effective amount of one or more additional enzyme selected from the group consisting of protease, xylanase, beta-glucanase, phytase, and amylase.

### Claim 10 (depends on 1)

The method of claim 1, wherein (i) the alpha-L-1,2 fucosidase and/or additional enzyme is encapsulated; (ii) the alpha-L-1.2 fucosidase and/or the direct fed microbial and/or the additional enzyme are administered in an animal feed or a premix; and/or (iii) the alpha-L-1,2 fucosidase and/or additional enzyme is in the form of a granule.

### Claim at position 11

11-12. (canceled)

### Claim 13 (depends on 1)

The method of claim 1, wherein the animal is swine.

### Claim at position 13

14-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, wherein the glycoside hydrolase capable of removing at least one alpha-1,2-L-fucose moiety from an intestinal mucin layer is not administered for treatment or prevention of intestinal pathogenic infection and/or diarrhea.

### Claim 17 (depends on 1)

The method of claim 1, wherein the glycoside hydrolase capable of removing at least one alpha-1,2-L-fucose moiety from an intestinal mucin layer is administered for at least 3 weeks.

### Claim 18 (depends on 2)

The method of claim 2, wherein the intestinal IgA is bound to fecal microbes.

### Claim 19

A method for decreasing methane emissions in an animal comprising administering to the animal an effective amount of a glycoside hydrolase capable of removing at least one alpha-1,2-L-fucose moiety from an intestinal mucin layer.

### Claim 20 (depends on 19)

The method of claim 19, wherein the decreased methane emissions result from decreased growth of one or more methanogenic archaea in the intestinal tract if the animal.

### Claim 21 (depends on 19)

The method if claim 19, wherein the methanogenic archaea comprises Methanobrevibacter spp.

### Claim 22 (depends on 19)

The method of claim 19, wherein the methanogenic archaea comprises M. smithii.

### Claim 23 (depends on 19)

The method of claim 19, wherein the glycoside hydrolase is an alpha-L-1,2 fucosidase.

### Claim 24 (depends on 23)

The method of claim 23, wherein the alpha-L-1,2 fucosidase is selected from the group consisting of glycoside hydrolase family 95 (GH95) and glycoside hydrolase family 29 (GH 29).

### Claim 25 (depends on 19)

The method of claim 19, wherein the alpha-L-1,2 fucosidase is (i) encapsulated; (ii) in an animal feed or a premix; (iii) and/or in the form of a granule.

### Claim at position 24

26-27. (canceled)

### Claim 28 (depends on 19)

The method of claim 19, wherein the animal is swine.

### Claim at position 26

29-30. (canceled)

### Claim 31 (depends on 19)

The method of claim 19, wherein the glycoside hydrolase capable of removing at least one alpha-1,2-L-fucose moiety from an intestinal mucin layer is administered for at least 3 weeks.
